Science Explorer Back to mapMap
Discussion
Researcher · Eon Corporation (United States) · United States

David A. Eiznhamer

David A. Eiznhamer publishes mostly in Molecular Biology, Hematology and Oncology, on topics such as Hematopoietic Stem Cell Transplantation, Acute Lymphoblastic Leukemia research and Plant biochemistry and biosynthesis.

OpenAlex
World rank
#2,514,139
of 7,710,434 ranked researchers
Rank in United States
#740,814
of 1,627,098
Works
35
Citations
1.3k
Citations per work
35.8
h-index
14
i10-index 17Top 55% in Molecular Biology
David A. Eiznhamer

What does David A. Eiznhamer research?

David A. Eiznhamer's work is mostly in Medicine (38%), Biochemistry, Genetics and Molecular Biology (19%), Immunology and Microbiology (8%).

Health Sciences: 13 works · 37.5% of their workMedicine: 13 works · 37.5% of their workHematology: 5 works · 15.4% of their workOncology: 3 works · 9.6% of their workPublic Health, Environmental and Occupational Health: 2 works · 6.7% of their workEpidemiology: 2 works · 5.8% of their workEverything else: 12 works · 35.6% of their workLife Sciences: 9 works · 26.9% of their workBiochemistry, Genetics and Molecular Biology: 7 works · 19.2% of their workMolecular Biology: 7 works · 19.2% of their workImmunology and Microbiology: 3 works · 7.7% of their workImmunology: 3 works · 7.7% of their workTHEIR WORKDavid A.Eiznhamer35works
Life Sciences27%Health Sciences38%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
    1. Medicine1337.5%
  2. Everything else1235.6%
    1. Biochemistry, Genetics and Molecular Biology719.2%
    2. Immunology and Microbiology37.7%
  1. 1Molecular Biology19% of their works
  2. 2Hematology15% of their works
  3. 3Oncology10% of their works
  4. 4Immunology8% of their works
  5. 5Public Health, Environmental and Occupational Health7% of their works
  6. 6Epidemiology6% of their works

Research topics

Which keywords describe David A. Eiznhamer's research?

The keywords of their largest research topics: Bone Marrow Niche, Hematopoietic Stem Cells, Prognostic Factors, Acute Lymphoblastic Leukemia, Childhood Cancer, Isoprenoid Pathway, Terpenoid Biosynthesis and Saponins.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 17 words, with their numbers
  1. Bone Marrow Niche101 topic
  2. Hematopoietic Stem Cells101 topic
  3. Prognostic Factors102 topics
  4. Acute Lymphoblastic Leukemia71 topic
  5. Childhood Cancer71 topic
  6. Isoprenoid Pathway61 topic
  7. Terpenoid Biosynthesis61 topic
  8. Saponins51 topic
  9. Triterpenoids51 topic
  10. CAR T Cells41 topic
  11. Chimeric Antigen Receptor41 topic
  12. Community-Acquired Pneumonia41 topic
  13. Pneumococcal Conjugate Vaccine41 topic
  14. Chronic Lymphocytic Leukemia31 topic
  15. Genomic Aberrations31 topic
  16. Pattern Recognition Receptors31 topic
  17. Toll-like Receptors31 topic

Where does David A. Eiznhamer work?

David A. Eiznhamer's main affiliation in the publication record is Eon Corporation (United States), United States.

How many publications and citations does David A. Eiznhamer have?

OpenAlex counts 35 works and 1,252 citations for David A. Eiznhamer, an h-index of 14, ranking #2,514,139 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about David A. Eiznhamer. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.